Retinal Ganglion Cell Functional Recovery after Intraocular Pressure Lowering Treatment Using Prostaglandin Analogs in Glaucoma Suspects: A Prospective Pilot Study
To evaluate the ability of pattern electroretinogram (PERG) to detect improvement of retinal ganglion cell (RGC) function in glaucoma suspects (GS) after medically reducing intraocular pressure (IOP) using prostaglandin analog drops. Six subjects (eight eyes) received topical IOP lowering treatment...
Saved in:
Published in | Journal of current glaucoma practice Vol. 17; no. 4; pp. 178 - 190 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
India
Jaypee Brothers Medical Publishers
01.10.2023
|
Subjects | |
Online Access | Get full text |
ISSN | 0974-0333 0975-1947 |
DOI | 10.5005/jp-journals-10078-1423 |
Cover
Abstract | To evaluate the ability of pattern electroretinogram (PERG) to detect improvement of retinal ganglion cell (RGC) function in glaucoma suspects (GS) after medically reducing intraocular pressure (IOP) using prostaglandin analog drops.
Six subjects (eight eyes) received topical IOP lowering treatment based on their clinical examination and were observed at Manhattan Eye, Ear & Throat Hospital over an average of 3.1 ± 2.2 months. During this time, participants underwent a full ophthalmologic exam and were evaluated with a Humphrey visual field analyzer (HFA) 24-2 [24-2 mean deviation (MD), 24-2 pattern standard deviation (PSD), and 24-2 visual field indices (VFI)], Diopsys NOVA PERG optimized for glaucoma [magnitude (Mag), magnitudeD (MagD), and magnitudeD/magnitude ratio (MagD/Mag ratio)] and optical coherence tomography (OCT)-derived average retinal nerve fiber layer thickness (avRNFLT) and average ganglion cell layer + inner plexiform layer (avGCL + IPL) thicknesses at baseline visit (pretreatment) and 3 months later (posttreatment). Goldman applanation tonometry was used to measure IOP at each visit. Paired sample
-tests were conducted to determine the statistical significance of the change in IOP, HFA indices, PERG parameters, and OCT thickness measurements between the two visits.
Lowering IOP by 22.29% resulted in a significant increase (32.98 and 15.49%) in MagD [
(7) = -3.174, 95% confidence interval (CI) = -0.53, -0.08,
= 0.016] and MagD/Mag ratio [
(7) = -3.233, 95% CI = -0.20, -0.03,
= 0.014], respectively. There was a positive percentage change for all variables of interest, however, 24-2 MD, Mag, avRNFLT, and GCL+ IPLT did not reach statistical significance.
After reducing IOP by 22.29% for a duration of 3.1 months, the PERG parameters, MagD and MagD/Mag ratio, significantly improved by 32.98 and 15.49%, respectively.
Pattern electroretinogram (PERG) may be a crucial tool for clinicians to locate a window of opportunity in which degenerating yet viable RGCs could be rescued from irreversible damage. We suggest consideration of PERG as a tool in early retinal ganglion cell (RGC) dysfunction detection as well as for monitoring IOP lowering treatment.
Tirsi A, Gliagias V, Sheha H,
Retinal Ganglion Cell Functional Recovery after Intraocular Pressure Lowering Treatment Using Prostaglandin Analogs in Glaucoma Suspects: A Prospective Pilot Study. J Curr Glaucoma Pract 2023;17(4):178-190. |
---|---|
AbstractList | To evaluate the ability of pattern electroretinogram (PERG) to detect improvement of retinal ganglion cell (RGC) function in glaucoma suspects (GS) after medically reducing intraocular pressure (IOP) using prostaglandin analog drops.Aim and backgroundTo evaluate the ability of pattern electroretinogram (PERG) to detect improvement of retinal ganglion cell (RGC) function in glaucoma suspects (GS) after medically reducing intraocular pressure (IOP) using prostaglandin analog drops.Six subjects (eight eyes) received topical IOP lowering treatment based on their clinical examination and were observed at Manhattan Eye, Ear & Throat Hospital over an average of 3.1 ± 2.2 months. During this time, participants underwent a full ophthalmologic exam and were evaluated with a Humphrey visual field analyzer (HFA) 24-2 [24-2 mean deviation (MD), 24-2 pattern standard deviation (PSD), and 24-2 visual field indices (VFI)], Diopsys NOVA PERG optimized for glaucoma [magnitude (Mag), magnitudeD (MagD), and magnitudeD/magnitude ratio (MagD/Mag ratio)] and optical coherence tomography (OCT)-derived average retinal nerve fiber layer thickness (avRNFLT) and average ganglion cell layer + inner plexiform layer (avGCL + IPL) thicknesses at baseline visit (pretreatment) and 3 months later (posttreatment). Goldman applanation tonometry was used to measure IOP at each visit. Paired sample t-tests were conducted to determine the statistical significance of the change in IOP, HFA indices, PERG parameters, and OCT thickness measurements between the two visits.Materials and methodsSix subjects (eight eyes) received topical IOP lowering treatment based on their clinical examination and were observed at Manhattan Eye, Ear & Throat Hospital over an average of 3.1 ± 2.2 months. During this time, participants underwent a full ophthalmologic exam and were evaluated with a Humphrey visual field analyzer (HFA) 24-2 [24-2 mean deviation (MD), 24-2 pattern standard deviation (PSD), and 24-2 visual field indices (VFI)], Diopsys NOVA PERG optimized for glaucoma [magnitude (Mag), magnitudeD (MagD), and magnitudeD/magnitude ratio (MagD/Mag ratio)] and optical coherence tomography (OCT)-derived average retinal nerve fiber layer thickness (avRNFLT) and average ganglion cell layer + inner plexiform layer (avGCL + IPL) thicknesses at baseline visit (pretreatment) and 3 months later (posttreatment). Goldman applanation tonometry was used to measure IOP at each visit. Paired sample t-tests were conducted to determine the statistical significance of the change in IOP, HFA indices, PERG parameters, and OCT thickness measurements between the two visits.Lowering IOP by 22.29% resulted in a significant increase (32.98 and 15.49%) in MagD [t (7) = -3.174, 95% confidence interval (CI) = -0.53, -0.08, p = 0.016] and MagD/Mag ratio [t (7) = -3.233, 95% CI = -0.20, -0.03, p = 0.014], respectively. There was a positive percentage change for all variables of interest, however, 24-2 MD, Mag, avRNFLT, and GCL+ IPLT did not reach statistical significance.ResultsLowering IOP by 22.29% resulted in a significant increase (32.98 and 15.49%) in MagD [t (7) = -3.174, 95% confidence interval (CI) = -0.53, -0.08, p = 0.016] and MagD/Mag ratio [t (7) = -3.233, 95% CI = -0.20, -0.03, p = 0.014], respectively. There was a positive percentage change for all variables of interest, however, 24-2 MD, Mag, avRNFLT, and GCL+ IPLT did not reach statistical significance.After reducing IOP by 22.29% for a duration of 3.1 months, the PERG parameters, MagD and MagD/Mag ratio, significantly improved by 32.98 and 15.49%, respectively.ConclusionAfter reducing IOP by 22.29% for a duration of 3.1 months, the PERG parameters, MagD and MagD/Mag ratio, significantly improved by 32.98 and 15.49%, respectively.Pattern electroretinogram (PERG) may be a crucial tool for clinicians to locate a window of opportunity in which degenerating yet viable RGCs could be rescued from irreversible damage. We suggest consideration of PERG as a tool in early retinal ganglion cell (RGC) dysfunction detection as well as for monitoring IOP lowering treatment.Clinical significancePattern electroretinogram (PERG) may be a crucial tool for clinicians to locate a window of opportunity in which degenerating yet viable RGCs could be rescued from irreversible damage. We suggest consideration of PERG as a tool in early retinal ganglion cell (RGC) dysfunction detection as well as for monitoring IOP lowering treatment.Tirsi A, Gliagias V, Sheha H, et al. Retinal Ganglion Cell Functional Recovery after Intraocular Pressure Lowering Treatment Using Prostaglandin Analogs in Glaucoma Suspects: A Prospective Pilot Study. J Curr Glaucoma Pract 2023;17(4):178-190.How to cite this articleTirsi A, Gliagias V, Sheha H, et al. Retinal Ganglion Cell Functional Recovery after Intraocular Pressure Lowering Treatment Using Prostaglandin Analogs in Glaucoma Suspects: A Prospective Pilot Study. J Curr Glaucoma Pract 2023;17(4):178-190. To evaluate the ability of pattern electroretinogram (PERG) to detect improvement of retinal ganglion cell (RGC) function in glaucoma suspects (GS) after medically reducing intraocular pressure (IOP) using prostaglandin analog drops. Six subjects (eight eyes) received topical IOP lowering treatment based on their clinical examination and were observed at Manhattan Eye, Ear & Throat Hospital over an average of 3.1 ± 2.2 months. During this time, participants underwent a full ophthalmologic exam and were evaluated with a Humphrey visual field analyzer (HFA) 24-2 [24-2 mean deviation (MD), 24-2 pattern standard deviation (PSD), and 24-2 visual field indices (VFI)], Diopsys NOVA PERG optimized for glaucoma [magnitude (Mag), magnitudeD (MagD), and magnitudeD/magnitude ratio (MagD/Mag ratio)] and optical coherence tomography (OCT)-derived average retinal nerve fiber layer thickness (avRNFLT) and average ganglion cell layer + inner plexiform layer (avGCL + IPL) thicknesses at baseline visit (pretreatment) and 3 months later (posttreatment). Goldman applanation tonometry was used to measure IOP at each visit. Paired sample -tests were conducted to determine the statistical significance of the change in IOP, HFA indices, PERG parameters, and OCT thickness measurements between the two visits. Lowering IOP by 22.29% resulted in a significant increase (32.98 and 15.49%) in MagD [ (7) = -3.174, 95% confidence interval (CI) = -0.53, -0.08, = 0.016] and MagD/Mag ratio [ (7) = -3.233, 95% CI = -0.20, -0.03, = 0.014], respectively. There was a positive percentage change for all variables of interest, however, 24-2 MD, Mag, avRNFLT, and GCL+ IPLT did not reach statistical significance. After reducing IOP by 22.29% for a duration of 3.1 months, the PERG parameters, MagD and MagD/Mag ratio, significantly improved by 32.98 and 15.49%, respectively. Pattern electroretinogram (PERG) may be a crucial tool for clinicians to locate a window of opportunity in which degenerating yet viable RGCs could be rescued from irreversible damage. We suggest consideration of PERG as a tool in early retinal ganglion cell (RGC) dysfunction detection as well as for monitoring IOP lowering treatment. Tirsi A, Gliagias V, Sheha H, Retinal Ganglion Cell Functional Recovery after Intraocular Pressure Lowering Treatment Using Prostaglandin Analogs in Glaucoma Suspects: A Prospective Pilot Study. J Curr Glaucoma Pract 2023;17(4):178-190. |
Author | Tirsi, Andrew Moehringer, Julie Gliagias, Vasiliki Gupta, Rohun Obstbaum, Stephen A Tsai, Joby Sheha, Hosam Tello, Celso Patel, Bhakti |
AuthorAffiliation | 6 Broward Health Medical Center, Fort Lauderdale, United States 5 Sanford H. Calhoun High School, Merrick, New York, United States 1,3,8,9 Manhattan Eye, Ear and Throat Hospital; Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell Health, Hempstead, New York, United States 2,4,7 Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell Health, Hempstead, New York, United States |
AuthorAffiliation_xml | – name: 6 Broward Health Medical Center, Fort Lauderdale, United States – name: 2,4,7 Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell Health, Hempstead, New York, United States – name: 1,3,8,9 Manhattan Eye, Ear and Throat Hospital; Donald and Barbara Zucker School of Medicine at Hofstra University/Northwell Health, Hempstead, New York, United States – name: 5 Sanford H. Calhoun High School, Merrick, New York, United States |
Author_xml | – sequence: 1 givenname: Hosam surname: Sheha fullname: Sheha, Hosam – sequence: 2 givenname: Andrew surname: Tirsi fullname: Tirsi, Andrew – sequence: 3 givenname: Vasiliki surname: Gliagias fullname: Gliagias, Vasiliki – sequence: 4 givenname: Bhakti surname: Patel fullname: Patel, Bhakti – sequence: 5 givenname: Julie surname: Moehringer fullname: Moehringer, Julie – sequence: 6 givenname: Joby surname: Tsai fullname: Tsai, Joby – sequence: 7 givenname: Rohun surname: Gupta fullname: Gupta, Rohun – sequence: 8 givenname: Stephen A surname: Obstbaum fullname: Obstbaum, Stephen A – sequence: 9 givenname: Celso surname: Tello fullname: Tello, Celso |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38269268$$D View this record in MEDLINE/PubMed |
BookMark | eNqFUttq3DAQFSWlSdP8QtBjX9zKli1bpVCWpdkGFrrk8iy00tjVYkuuJG_Y7-mPVt5caPtSgdAMc-aMZua8RSfWWUDoMicfKkKqj7sx27nJW9mHLCekbrK8LOgrdEZ4XWU5L-uTo11mhFJ6ii5C2JF0ynQ5f4NOaVMwXrDmDP26gWgSEV5J2_XGWbyEvsdXk1UxeSlwA8rtwR-wbCN4fG2jl05NvfR44yGEyQNeuwfwxnb4zoOMA9iI78Psb7wLUXa9tNpYvEh8rgs4mateTsoNEt9OYQQVwye8OKJnx-wBb0zvIr6Nkz68Q6_b1CpcPL3n6P7q693yW7b-vrpeLtaZKhihmQYGnFWUFVtdSclYVepcsqZVumxyluYB29R3zRsN0BLGoa64rhsgoNt2q-k5-vLIO07bAbSCudVejN4M0h-Ek0b8HbHmh-jcXuSkIbSoy8Tw_onBu58ThCgGE1QaqLTgpiAKnjdVTquKJOjln8VeqjyvJgHYI0ClqQQP7QskJ2KWgdiN4lkG4igDMcsgJX7-J1GZKOdtpk-b_n_pvwHwfsKf |
CitedBy_id | crossref_primary_10_2147_OPTH_S483055 crossref_primary_10_1159_000542199 crossref_primary_10_31083_j_fbl2912410 |
Cites_doi | 10.1017/S0952523899163028 10.1167/iovs.13-12634 10.1016/j.ophtha.2007.08.023 10.1167/iovs.04-0199 10.1167/tvst.7.1.11 10.1007/s10633-020-09760-5 10.1016/j.ophtha.2008.10.026 10.1016/j.ophtha.2015.06.015 10.1016/j.ophtha.2008.12.032 10.1159/000267663 10.4103/tjo.tjo_106_17 10.1016/j.ophtha.2003.04.007 10.1001/archopht.120.10.1268 10.1016/j.visres.2010.08.036 10.1016/j.ophtha.2004.09.002 10.1155/2021/8025337 10.1007/s10633-017-9575-0 10.1016/j.exer.2011.01.014 10.1007/BF02133775 10.1007/BF00146546 10.1007/s40123-020-00302-5 10.5005/jp-journals-10078-1365 10.1007/s10633-022-09869-9 10.1371/journal.pone.0214875 10.1023/A:1020553020264 10.1097/IJG.0b013e31819afb5c 10.3928/15428877-20121001-01 10.1016/j.ophtha.2010.08.049 10.1007/s10633-007-9053-1 10.1038/s41433-021-01603-0 10.1097/IJG.0b013e318193c2e1 10.1016/j.exer.2015.05.008 10.1186/s12889-019-6935-6 10.1167/iovs.11-7896 10.1159/000310622 10.1016/j.ophtha.2004.07.018 10.1097/IJG.0000000000000203 10.1371/journal.pone.0220992 10.1097/IJG.0000000000001103 10.1007/s10633-022-09900-z 10.1167/iovs.12-10345 10.1167/iovs.12-11026 10.3238/arztebl.2009.0597 10.1001/archopht.120.6.701 10.1167/iovs.03-1411 10.3390/cells10061398 |
ContentType | Journal Article |
Copyright | Copyright © 2023; The Author(s). Copyright © 2023; The Author(s). 2023 |
Copyright_xml | – notice: Copyright © 2023; The Author(s). – notice: Copyright © 2023; The Author(s). 2023 |
DBID | AAYXX CITATION NPM 7X8 5PM |
DOI | 10.5005/jp-journals-10078-1423 |
DatabaseName | CrossRef PubMed MEDLINE - Academic PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic PubMed |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 0975-1947 |
EndPage | 190 |
ExternalDocumentID | PMC10803274 38269268 10_5005_jp_journals_10078_1423 |
Genre | Journal Article |
GroupedDBID | --- 8R4 8R5 AAYXX ACZLU ADBBV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL CITATION DIK EMOBN HYE KQ8 M48 OK1 PGMZT PW6 Q2X RPM SV3 ADRAZ NPM 7X8 5PM |
ID | FETCH-LOGICAL-c2603-de6e965362bd5aa6654d1a68fcd4816097eb826798deef069e759d78e0edffbd3 |
IEDL.DBID | M48 |
ISSN | 0974-0333 |
IngestDate | Thu Aug 21 18:36:16 EDT 2025 Fri Jul 11 06:44:11 EDT 2025 Thu Jan 02 22:27:28 EST 2025 Tue Jul 01 00:45:44 EDT 2025 Thu Apr 24 23:04:30 EDT 2025 |
IsDoiOpenAccess | true |
IsOpenAccess | true |
IsPeerReviewed | false |
IsScholarly | true |
Issue | 4 |
Keywords | Retinal ganglion cells Glaucoma suspects Ganglion cell layer + inner plexiform layer Retinal nerve fiber layer thickness Pattern electroretinogram Intraocular pressure treatment |
Language | English |
License | Copyright © 2023; The Author(s). The Author(s). 2023 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by-nc/4.0/), which permits unrestricted use, distribution, and non-commercial reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c2603-de6e965362bd5aa6654d1a68fcd4816097eb826798deef069e759d78e0edffbd3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.5005/jp-journals-10078-1423 |
PMID | 38269268 |
PQID | 2918513550 |
PQPubID | 23479 |
PageCount | 13 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_10803274 proquest_miscellaneous_2918513550 pubmed_primary_38269268 crossref_primary_10_5005_jp_journals_10078_1423 crossref_citationtrail_10_5005_jp_journals_10078_1423 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2023 Oct-Dec |
PublicationDateYYYYMMDD | 2023-10-01 |
PublicationDate_xml | – month: 10 year: 2023 text: 2023 Oct-Dec |
PublicationDecade | 2020 |
PublicationPlace | India |
PublicationPlace_xml | – name: India |
PublicationTitle | Journal of current glaucoma practice |
PublicationTitleAlternate | J Curr Glaucoma Pract |
PublicationYear | 2023 |
Publisher | Jaypee Brothers Medical Publishers |
Publisher_xml | – name: Jaypee Brothers Medical Publishers |
References | ref=27 ref=26 ref=25 ref=24 ref=23 ref=22 ref=21 ref=20 ref=1 ref=29 ref=28 ref=7 ref=6 ref=9 ref=8 ref=3 ref=2 ref=5 ref=4 ref=30 ref=38 ref=37 ref=36 ref=35 ref=34 ref=33 ref=32 ref=31 ref=39 ref=41 ref=40 ref=49 ref=48 ref=47 ref=46 ref=45 ref=44 ref=43 ref=42 ref=52 ref=51 ref=50 ref=16 ref=15 ref=14 ref=13 ref=12 ref=11 ref=55 ref=10 ref=54 ref=53 ref=19 ref=18 ref=17 |
References_xml | – ident: ref=18 doi: 10.1017/S0952523899163028 – ident: ref=7 – ident: ref=44 doi: 10.1167/iovs.13-12634 – ident: ref=3 – ident: ref=39 doi: 10.1016/j.ophtha.2007.08.023 – ident: ref=36 doi: 10.1167/iovs.04-0199 – ident: ref=49 doi: 10.1167/tvst.7.1.11 – ident: ref=54 doi: 10.1007/s10633-020-09760-5 – ident: ref=38 doi: 10.1016/j.ophtha.2008.10.026 – ident: ref=12 doi: 10.1016/j.ophtha.2015.06.015 – ident: ref=43 doi: 10.1016/j.ophtha.2008.12.032 – ident: ref=24 doi: 10.1159/000267663 – ident: ref=48 doi: 10.4103/tjo.tjo_106_17 – ident: ref=19 – ident: ref=14 doi: 10.1016/j.ophtha.2003.04.007 – ident: ref=27 doi: 10.1001/archopht.120.10.1268 – ident: ref=30 doi: 10.1016/j.visres.2010.08.036 – ident: ref=55 – ident: ref=6 doi: 10.1016/j.ophtha.2004.09.002 – ident: ref=8 doi: 10.1155/2021/8025337 – ident: ref=28 doi: 10.1007/s10633-017-9575-0 – ident: ref=42 doi: 10.1016/j.exer.2011.01.014 – ident: ref=20 doi: 10.1007/BF02133775 – ident: ref=22 doi: 10.1007/BF00146546 – ident: ref=51 doi: 10.1007/s40123-020-00302-5 – ident: ref=26 – ident: ref=35 doi: 10.5005/jp-journals-10078-1365 – ident: ref=23 – ident: ref=33 doi: 10.1007/s10633-022-09869-9 – ident: ref=32 doi: 10.1371/journal.pone.0214875 – ident: ref=17 doi: 10.1023/A:1020553020264 – ident: ref=37 doi: 10.1097/IJG.0b013e31819afb5c – ident: ref=5 – ident: ref=50 doi: 10.3928/15428877-20121001-01 – ident: ref=15 doi: 10.1016/j.ophtha.2010.08.049 – ident: ref=40 doi: 10.1007/s10633-007-9053-1 – ident: ref=31 doi: 10.1038/s41433-021-01603-0 – ident: ref=53 doi: 10.1097/IJG.0b013e318193c2e1 – ident: ref=1 doi: 10.1016/j.exer.2015.05.008 – ident: ref=11 doi: 10.1186/s12889-019-6935-6 – ident: ref=46 doi: 10.1167/iovs.11-7896 – ident: ref=2 – ident: ref=25 doi: 10.1159/000310622 – ident: ref=52 doi: 10.1016/j.ophtha.2004.07.018 – ident: ref=45 doi: 10.1097/IJG.0000000000000203 – ident: ref=41 doi: 10.1371/journal.pone.0220992 – ident: ref=10 doi: 10.1097/IJG.0000000000001103 – ident: ref=34 doi: 10.1007/s10633-022-09900-z – ident: ref=9 doi: 10.1167/iovs.12-10345 – ident: ref=13 doi: 10.1167/iovs.12-11026 – ident: ref=21 – ident: ref=29 doi: 10.3238/arztebl.2009.0597 – ident: ref=4 doi: 10.1001/archopht.120.6.701 – ident: ref=16 doi: 10.1167/iovs.03-1411 – ident: ref=47 doi: 10.3390/cells10061398 |
SSID | ssj0000400099 |
Score | 2.2408369 |
Snippet | To evaluate the ability of pattern electroretinogram (PERG) to detect improvement of retinal ganglion cell (RGC) function in glaucoma suspects (GS) after... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 178 |
SubjectTerms | Original Research |
Title | Retinal Ganglion Cell Functional Recovery after Intraocular Pressure Lowering Treatment Using Prostaglandin Analogs in Glaucoma Suspects: A Prospective Pilot Study |
URI | https://www.ncbi.nlm.nih.gov/pubmed/38269268 https://www.proquest.com/docview/2918513550 https://pubmed.ncbi.nlm.nih.gov/PMC10803274 |
Volume | 17 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1Nb9QwELVKkRCXClqgC6UyEle368Rx7F6qqmLbIhZV0JV6ixzbga2iZNkPqft7-kc74yQrtlTALVLsRMlMMu_ZM_MI-WiklQhTGfz9cyasLVguNGfA27xRnFsX-swOv8rzkfh8nVxvkE4utX2Bs0epHepJjablwe2v5TF88IBfDxJwosObCevmMdz0B1oEIOEJeQrRSSIhG7aQP_ydRUBFoQVfKlg_juOmcPgvl1qPWX8A0Yf5lL8FqMELstUiS3rSuMJLsuGrbfJs2O6d75C7b1jdDCPODJbu1hU99WVJBxDYmvVAilQUPHtJg3A4vcDb1CFPlTZVhFNPv6CqGoQ7etVlqNOQdQAjagCaQRFkXFHsdVL_mFE4PCvNAtza0O-LUNY5O6InYXRb40kvx2U9p5jQuHxFRoNPV6fnrJVoYBaIUMycl17LBKJg7hJjUMrYcSNVYZ1QXMIr9jkQmFQr533Rl9qniXap8n3viiJ38WuyWdWV3yUUDFFILXRuFRep43lkVeSLiLsYKJpIeiTpjJDZtn85ymiUGfAYNF52M8k644VWzCpD4_XI4WrepOng8c8ZHzobZ_Cx4Q6KqXy9mGWRBnjDAaL1e-RNY_PVNWN4Th1J1SNqzRtWA7CR9_qZavwzNPTGPM84SsXb_7jxO_IcFe-bfMI9sjmfLvx7wEXzfD84-n5YsLoHkw4Sxg |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Retinal+Ganglion+Cell+Functional+Recovery+after+Intraocular+Pressure+Lowering+Treatment+Using+Prostaglandin+Analogs+in+Glaucoma+Suspects%3A+A+Prospective+Pilot+Study&rft.jtitle=Journal+of+current+glaucoma+practice&rft.au=Tirsi%2C+Andrew&rft.au=Gliagias%2C+Vasiliki&rft.au=Sheha%2C+Hosam&rft.au=Patel%2C+Bhakti&rft.date=2023-10-01&rft.issn=0974-0333&rft.volume=17&rft.issue=4&rft.spage=178&rft_id=info:doi/10.5005%2Fjp-journals-10078-1423&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0974-0333&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0974-0333&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0974-0333&client=summon |